Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer.

Zelefsky MJ, Yamada Y, Pei X, Hunt M, Cohen G, Zhang Z, Zaider M.

Urology. 2011 Apr;77(4):986-90. doi: 10.1016/j.urology.2010.07.539. Epub 2010 Dec 31.

2.

Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.

Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR.

Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):904-12.

PMID:
12095556
3.

Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.

Spratt DE, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, Cohen G, Polkinghorn W, Yamada Y, Zelefsky MJ.

BJU Int. 2014 Sep;114(3):360-7. doi: 10.1111/bju.12514. Epub 2014 Jan 22.

4.

High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.

J Urol. 2001 Sep;166(3):876-81. Erratum in: J Urol 2001 Nov;166(5):1839.

PMID:
11490237
5.

Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.

Morimoto M, Yoshioka Y, Konishi K, Isohashi F, Takahashi Y, Ogata T, Koizumi M, Teshima T, Bijl HP, van der Schaaf A, Langendijk JA, Ogawa K.

Tumori. 2014 May-Jun;100(3):265-71. doi: 10.1700/1578.17198.

PMID:
25076236
6.

Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.

Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen GN, Zaider M, Zelefsky MJ.

Brachytherapy. 2013 Jan-Feb;12(1):44-9. doi: 10.1016/j.brachy.2012.05.003. Epub 2012 Jul 24.

7.

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA.

J Clin Oncol. 1999 Feb;17(2):517-22.

PMID:
10080594
8.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

9.

Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.

Gómez-Iturriaga Piña A, Crook J, Borg J, Ma C.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):422-7. doi: 10.1016/j.ijrobp.2009.07.1723.

PMID:
20832665
10.

Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.

Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.

Brachytherapy. 2008 Jan-Mar;7(1):1-6. doi: 10.1016/j.brachy.2007.12.002.

PMID:
18299108
11.

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H.

J Urol. 2006 Oct;176(4 Pt 1):1415-9.

PMID:
16952647
12.
13.

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9. doi: 10.1016/j.ijrobp.2011.11.047. Epub 2012 Feb 11.

PMID:
22330997
14.

Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.

Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.

Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30.

PMID:
22853851
15.

Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.

Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):898-905. doi: 10.1016/j.ijrobp.2010.11.003. Epub 2011 Jan 14.

PMID:
21237581
16.

High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.

Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1889-96. doi: 10.1016/j.ijrobp.2010.09.006. Epub 2011 May 6.

PMID:
21550182
17.

Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.

Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):686-92. doi: 10.1016/j.ijrobp.2012.05.023. Epub 2012 Jul 12.

PMID:
22795805
18.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
19.

Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.

Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8. Epub 2005 Sep 19.

PMID:
16169683
20.

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.

Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z.

Eur Urol. 2011 Dec;60(6):1133-9. doi: 10.1016/j.eururo.2011.08.029. Epub 2011 Aug 22.

Items per page

Supplemental Content

Write to the Help Desk